INFOGRAPHIC: XEOMIN® (incobotulinumtoxinA) PEDIATRIC CHRONIC SIALORRHEA
|XEOMIN® (incobotulinumtoxinA) is now approved by the FDA for the treatment of patients aged 2 years and older with chronic sialorrhea, or drooling. XEOMIN is the first and only FDA-approved neuromodulator with this indication. You can read the full announcement here.
View our animated infographic detailing our latest approval by clicking the image below:
For a downloadable PDF version, click here.
Merz North America